Title |
Cost-effectiveness analysis of parenteral antimicrobials for acute melioidosis in Thailand
|
---|---|
Published in |
Transactions of the Royal Society of Tropical Medicine & Hygiene, May 2015
|
DOI | 10.1093/trstmh/trv002 |
Pubmed ID | |
Authors |
Viriya Hantrakun, Wirongrong Chierakul, Ploenchan Chetchotisakd, Siriluck Anunnatsiri, Bart J. Currie, Sharon J. Peacock, Nicholas P. J. Day, Phaik Cheah, Direk Limmathurotsakul, Yoel Lubell |
Abstract |
Melioidosis is a common community-acquired infectious disease in northeast Thailand associated with overall mortality of approximately 40% in hospitalized patients, and over 70% in severe cases. Ceftazidime is recommended for parenteral treatment in patients with suspected melioidosis. Meropenem is increasingly used but evidence to support this is lacking. A decision tree was used to estimate the cost-effectiveness of treating non-severe and severe suspected acute melioidosis cases with either ceftazidime or meropenem. Empirical treatment with meropenem is likely to be cost-effective providing meropenem reduces mortality in severe cases by at least 9% and the proportion with subsequent culture-confirmed melioidosis is over 20%. In this context, treatment of severe cases with meropenem is likely to be cost-effective, while the evidence to support the use of meropenem in non-severe suspected melioidosis is not yet available. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 24 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 5 | 21% |
Student > Master | 3 | 13% |
Other | 2 | 8% |
Student > Ph. D. Student | 2 | 8% |
Student > Postgraduate | 2 | 8% |
Other | 2 | 8% |
Unknown | 8 | 33% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 10 | 42% |
Environmental Science | 1 | 4% |
Biochemistry, Genetics and Molecular Biology | 1 | 4% |
Immunology and Microbiology | 1 | 4% |
Linguistics | 1 | 4% |
Other | 2 | 8% |
Unknown | 8 | 33% |